255 related articles for article (PubMed ID: 22967474)
1. [Population-based gastric cancer screening in Zhuanghe, Liaoning, from 1997 to 2011].
Yuan Y
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):538-42. PubMed ID: 22967474
[TBL] [Abstract][Full Text] [Related]
2. [Studies on the cut-off value of serum pepsinogen abnormality for screening chronic atrophic gastritis and gastric carcinoma].
Li YH; Zhang XH; Huang B; Wang JL; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Oct; 27(10):840-4. PubMed ID: 17343174
[TBL] [Abstract][Full Text] [Related]
3. [Dynamic monitoring of serum pepsinogen among high risk populations of gastric cancer in Zhuanghe county].
Sun LP; Gong YH; Wang L; Gong W; Yuan Y
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(40):2826-30. PubMed ID: 17200016
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of serum pepsinogen level and gastric mucosal changes of residents in the high incidence area of gastric cancer].
Zhang XH; Huang B; Wang JL; Li YH; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):507-11. PubMed ID: 17147114
[TBL] [Abstract][Full Text] [Related]
5. Serum pepsinogen test for early detection of gastric cancer in a European country.
Lomba-Viana R; Dinis-Ribeiro M; Fonseca F; Vieira AS; Bento MJ; Lomba-Viana H
Eur J Gastroenterol Hepatol; 2012 Jan; 24(1):37-41. PubMed ID: 21989121
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of two gastric cancer screening schemes in a high-risk population].
Lü YL; Li Y; Liu GS; Wu Q; Liu WD; Li SJ; Cao CQ; Wu XZ; Liu DM; Zhang L; Zhang LF; Ma JL; Pan KF; Zhang L; You WC
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):394-7. PubMed ID: 24054020
[TBL] [Abstract][Full Text] [Related]
7. Validity of serum pepsinogen levels and quininium resin test combined for gastric cancer screening.
Kim JR; Lee K; Jung WT; Lee OJ; Kim TH; Kim HJ; Lee JS; Passaro DJ
Cancer Detect Prev; 2005; 29(6):570-5. PubMed ID: 16289505
[TBL] [Abstract][Full Text] [Related]
8. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis.
Haj-Sheykholeslami A; Rakhshani N; Amirzargar A; Rafiee R; Shahidi SM; Nikbin B; Khosravi F; Massarrat S
Clin Gastroenterol Hepatol; 2008 Feb; 6(2):174-9. PubMed ID: 18237867
[TBL] [Abstract][Full Text] [Related]
9. [Study on health economics regarding the screening of gastric cancer in Zhuanghe high risk area].
Pan S; He QC; Zhou BS; Yuan Y
Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Oct; 26(10):757-60. PubMed ID: 16536299
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population.
Miki K; Fujishiro M; Kodashima S; Yahagi N
Dig Endosc; 2009 Apr; 21(2):78-81. PubMed ID: 19691778
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia.
Dinis-Ribeiro M; da Costa-Pereira A; Lopes C; Moreira-Dias L
J Gastroenterol Hepatol; 2007 Oct; 22(10):1594-604. PubMed ID: 17845687
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].
Gong YH; Sun LP; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):691-3. PubMed ID: 17274377
[TBL] [Abstract][Full Text] [Related]
13. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males.
Yanaoka K; Oka M; Mukoubayashi C; Yoshimura N; Enomoto S; Iguchi M; Magari H; Utsunomiya H; Tamai H; Arii K; Ohata H; Fujishiro M; Takeshita T; Mohara O; Ichinose M
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):838-45. PubMed ID: 18398025
[TBL] [Abstract][Full Text] [Related]
14. Follow-up study on a high risk population of gastric cancer in north China by serum pepsinogen assay.
Sun LP; Gong YH; Wang L; Gong W; Yuan Y
J Dig Dis; 2008 Feb; 9(1):20-6. PubMed ID: 18251790
[TBL] [Abstract][Full Text] [Related]
15. Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer.
Liu CY; Wu CY; Lin JT; Lee YC; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S2-5. PubMed ID: 17227633
[TBL] [Abstract][Full Text] [Related]
16. The non-invasive diagnosis of precancerous changes of stomach mucosa.
Pasechnikov VD; Chukov SZ; Kotelevets SM; Mostovov AN; Polyakova MB; Mernova VP
Rocz Akad Med Bialymst; 2004; 49():66-71. PubMed ID: 15631316
[TBL] [Abstract][Full Text] [Related]
17. [Potentialities of a serological method in diagnosis of atrophic gastritis].
Pimenov SI; Makarenko EV
Ter Arkh; 2008; 80(2):15-21. PubMed ID: 18372589
[TBL] [Abstract][Full Text] [Related]
18. Screening markers for chronic atrophic gastritis in Chiapas, Mexico.
Ley C; Mohar A; Guarner J; Herrera-Goepfert R; Figueroa LS; Halperin D; Parsonnet J
Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):107-12. PubMed ID: 11219766
[TBL] [Abstract][Full Text] [Related]
19. [Detection of gastric preneoplastic lesions with serum levels of pepsinogen in Chilean subjects].
Fernández F JI; de Aretxabala U X; Santander D R; Sabah T S; Maira S J; Navarro R A; Planzer D M; Gómez L F; Etchart M; Gallegos I; Torrens X; Fasce P G; Reydet I
Rev Med Chil; 2007 Dec; 135(12):1519-25. PubMed ID: 18357351
[TBL] [Abstract][Full Text] [Related]
20. [Serologic screening for preneoplastic pathology and early stomach cancer].
Maev IV; Mel'nikova EV; Kashin SV; Nadezhin AS; Kriukova TV
Klin Med (Mosk); 2008; 86(11):43-8. PubMed ID: 19177794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
